Diphtheria - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diphtheria - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diphtheria - Pipeline Review, H1 2015', provides an overview of the Diphtheria's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diphtheria
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diphtheria and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diphtheria pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diphtheria
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diphtheria Overview 9
Therapeutics Development 10
Pipeline Products for Diphtheria - Overview 10
Pipeline Products for Diphtheria - Comparative Analysis 11
Diphtheria - Therapeutics under Development by Companies 12
Diphtheria - Therapeutics under Investigation by Universities/Institutes 14
Diphtheria - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Diphtheria - Products under Development by Companies 19
Diphtheria - Products under Investigation by Universities/Institutes 21
Diphtheria - Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Biological E. Limited 23
Daiichi Sankyo Company, Limited 24
GlaxoSmithKline Plc 25
Green Cross Corporation 26
Indian Immunologicals Limited 27
LG Life Sciences, Ltd. 28
Panacea Biotec Limited 29
Prometheon Pharma, LLC 30
Sanofi 31
Sanofi Pasteur SA 32
Serum Institute of India Limited 33
Sinovac Biotech Ltd. 34
Zydus Cadila Healthcare Limited 35
Diphtheria - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(diphtheria + tetanus + pertussis) vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
diphtheria + pertussis + tetanus vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + tetanus vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
diphtheria vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
diphtheria vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GC-1107 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GC-3111A - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PR-5I - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
VN-0103 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Diphtheria - Recent Pipeline Updates 72
Diphtheria - Dormant Projects 73
Diphtheria - Discontinued Products 75
Diphtheria - Product Development Milestones 76
Featured News & Press Releases 76
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 76
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 76
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 77
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 77
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 78
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 79
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 79
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 80
Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series. 81
Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Diphtheria, H1 2015 10
Number of Products under Development for Diphtheria - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 22
Diphtheria - Pipeline by Biological E. Limited, H1 2015 23
Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 24
Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2015 25
Diphtheria - Pipeline by Green Cross Corporation, H1 2015 26
Diphtheria - Pipeline by Indian Immunologicals Limited, H1 2015 27
Diphtheria - Pipeline by LG Life Sciences, Ltd., H1 2015 28
Diphtheria - Pipeline by Panacea Biotec Limited, H1 2015 29
Diphtheria - Pipeline by Prometheon Pharma, LLC, H1 2015 30
Diphtheria - Pipeline by Sanofi, H1 2015 31
Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2015 32
Diphtheria - Pipeline by Serum Institute of India Limited, H1 2015 33
Diphtheria - Pipeline by Sinovac Biotech Ltd., H1 2015 34
Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Assessment by Combination Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Diphtheria Therapeutics - Recent Pipeline Updates, H1 2015 72
Diphtheria - Dormant Projects, H1 2015 73
Diphtheria - Dormant Projects (Contd..1), H1 2015 74
Diphtheria - Discontinued Products, H1 2015 75